qXR-CTR vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
qXR-CTR focuses on automating cardiothoracic ratio measurements from chest X-rays to assess general heart size and potential heart failure risk. In contrast, EchoGo Amyloidosis analyzes echocardiogram video clips specifically for the early detection of cardiac amyloidosis. While both are cardiology AI tools, their distinct imaging modalities and target conditions make them complementary rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
qXR-CTR is an AI-powered software designed to automate the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, primarily aiding in the assessment of heart size and potential heart failure risk. In contrast, EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
qXR-CTR analyzes chest X-ray images to calculate the cardiothoracic ratio. EchoGo Amyloidosis, on the other hand, analyzes echocardiogram video clips, specifically a single apical four-chamber view, to identify suspected cardiac amyloidosis.
The provided information for qXR-CTR does not include specific diagnostic performance metrics. EchoGo Amyloidosis reports high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis, with consistent performance across various CA subtypes (AL, wild-type ATTR, and variant ATTR).